NCT02837003

3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (estimated)
• Sponsor: Teikyo University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES). Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Aspirin	Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
DRUG	Thienopyridine	Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.

Timeline

• Start date: 2016-07-01
• Primary completion: 2019-03-01
• Completion: 2019-03-01
• First posted: 2016-07-19
• Last updated: 2016-08-02

Locations

1 site across 1 country: Japan